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Abstract
Objective: The aim of this study was to retrospectively analyze locally 
advanced buccal cancer in order to determine tumor characteristics and any 
other prognostic factors that may influence the survival of patients with 
the disease.
Patients and Methods: The records of 54 patients with stage III to IV 
locally advanced buccal cancer (TNM system) who were seen from August 
2000 to June 2008 at one institution were reviewed. The patients received 
radical surgery and then adjuvant treatment. The adjuvant treatment in cluded 
concurrent chemoradiotherapy or radiotherapy alone. The chemotherapy 
protocol consisted of two 4-weekly courses of concurrent cisplatin and 
5-fluorouracil followed by another two 4-weekly courses after radiotherapy, 
with regimens of cisplatin (60–100 mg/m2/day) on day 1 and 5-fluorouracil 
(1000 mg/m2/day) on days 1–5.
Results: The 3-year cumulative overall survival, disease-specific survival, 
disease-free survival, locoregional control, and distant metastasis-free sur-
vival rates were 66%, 69%, 58%, 65%, and 92%, respectively. Univariate 
analysis indicated that the pN classification, the surgical margin, and the 
presence of extracapsular spread were significantly associated with over-
all survival. On multivariate analysis, pN classification and surgical mar-
gin significantly affected disease-free survival. The pN classification (pN0 
vs. pN1–3) and the surgical margin (< 1 vs. ≥ 1 mm) were the two most 
significant factors affecting clinical outcome.
Conclusion: The presence of lymph node involvement, the presence of 
extracapsular spread and a surgical margin < 1 mm were strong prognos-
tic factors that were associated with tumor control. More aggressive post-
operative therapy is suggested for patients with buccal mucosa carcinoma 
if these factors exist. [Tzu Chi Med J 2010;22(2):96–102]
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1. Introduction
Buccal mucosa cancer is one of the major oral malig-
nancies. The incidence of buccal mucosa carcinoma 
has rapidly increased in Taiwan in recent decades; 
major risk factors for this disease are smoking, alcohol 
drinking, and betel nut chewing [1–5]. Nearly half of 
these patients will present with advanced disease and 
regional lymph node metastases [6]. Buccal cancer 
is locally aggressive with recurrence rates of 30–80% 
reported in the literature [7–9]. Moreover, locoregional 
recurrence remains the most frequent type of recur-
rence in patients with buccal cancer, and its incidence 
depends mainly on the site of the tumor, its clinical 
stage and its pathological characteristics. Numerous 
predictive factors in relation to the primary site and the 
neck, such as bone invasion or extension, resection 
margin, perineural invasion, vascular invasion, the 
presence of lymph node involvement and extracap-
sular extension of the lymph node involvement, are 
associated with locoregional recurrence [10]. Surgical 
excision combined with postoperative radiation has 
been recommended for advanced stage tumors [11]. 
Many studies have demonstrated superior locore-
gional control in advanced head and neck cancer 
when postoperative radiotherapy is used compared 
to treatment with surgery or radiation alone [12–16].
More recently, two large-scale randomized trials by 
the Radiation Therapy Oncology Group (RTOG) and 
the European Organization for Research Treatment 
of Cancer (EORTC) have demonstrated the benefits 
of adjuvant concurrent chemoradiotherapy (CCRT) 
after radical surgery in high-risk head-and-neck can-
cer patients; this infers that adjuvant CCRT should be 
used when there is extracapsular spread (ECS) and/
or an unclear margin [17,18]. However, these two trials 
included head and neck tumors from all sites, which 
may have blurred the differences in survival at differ-
ent sites. This study was a retrospective case analysis 
of locally advanced buccal cancers and the aim was 
to determine tumor characteristics, treatment patterns 
or any other prognostic factors that influence disease 
survival.
2. Patients and methods
The records of 60 patients with stage III to IV locally 
advanced buccal cancer (TNM system) [19] seen 
from August 2000 to June 2008 at one institution 
were reviewed. Six patients were excluded from anal-
ysis because they were either lost during follow-up 
(4 patients) or had a synchronous second primary 
(2 patients). All were diagnosed histologically with 
buccal cancer by pathologists and none had suffered 
from a previous cancer. All patients were informed 
about their disease treatment, including potential 
benefits and possible side effects. All patients were 
treated by a multidisciplinary group that included a 
head and neck surgery team, radiation oncologists, 
medical oncologists and dieticians.
2.1. Treatment
Radical surgery consisted of wide excision with or 
without flap reconstruction of the primary tumor and 
of unilateral or bilateral radical neck dissection for 
neck disease management. Pathology reports were 
reviewed for evidence of the size, grade, type, surgical 
margins, lymph node involvement, perineural inva-
sion, vascular permeation, lymphatic permeation and 
ECS of the tumor. Subclavian venous-access cathe-
ters were placed for nutritional support and the ad-
ministration of chemotherapy. Adjuvant treatments 
were started 4–6 weeks after surgery. Adjuvant CCRT 
was indicated for a positive margin, extracapsular 
nodal spread, or any combination of two other risk 
factors, including perineural invasion, vascular per-
meation, pT3, pT4 and N(+) nodal disease. Adjuvant 
radiotherapy (RT) was indicated for a single risk factor 
except for positive margin and extracapsular nodal 
spread.
Radiation therapy was delivered using the intensity-
modulated radiation technique via an inverse plan-
ning system (PLATO; Nucleotron Inc., Veenendaal, The 
Netherlands). The radiation field encompassed the 
primary tumor bed and neck lymph nodes. Treatment 
was delivered with a 6-MV multileaf collimator sys-
tem (Precise; Elekta Ltd., Crawley, UK) using a step-
and-shoot method with 7 coplanar beams.
The critical normal structures used for optimization 
included the brainstem, spinal cord, parotid glands, 
optic nerves, chiasm, lenses and eyeballs. Verifi-
cation of the treatment plan and dose was carried 
out before treatment and a weekly machine-check 
film involving electronic portal imaging was carried 
out to ensure set-up accuracy during treatment. The 
prescribed doses delivered by external beam RT were 
as follows: 70–72 Gy to the gross tumor volume; 
60–66 Gy to the high risk nodal region; and 50–60 Gy 
to the low risk nodal region. Conventional RT fraction-
ation was carried out, namely 1.8–2.0 Gy per day and 
5 days per week for 6–7 weeks. The spinal cord dose 
was limited to 45 Gy.
Chemotherapy was given concurrently with and 
after RT. The chemotherapy protocol consisted of 
two 4-weekly courses of concurrent cisplatin and 
5-fluorouracil (5-FU) followed by another two 4-weekly 
courses after RT, with regimens of cisplatin (60–
100 mg/m2/day) on day 1 and 5-FU (1000 mg/m2/day) 
on days 1–5. We evaluated treatment toxicity using 
the common toxicity criteria of the National Cancer 
Institute, V2.0 [20].
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2.2. Patient follow-up and patterns of 
failure
Patients were assessed at 3, 6 and 12 months and 
then every 6–12 months (or more often if clinically 
indicated) for 5 years. Survival was calculated from 
the date of diagnosis to the most recent follow-up or 
date of recurrence or death. The pattern of failure was 
defined according to the first site of failure. Local 
failure was defined as recurrence of the primary 
tumor. Locoregional failure was defined as recurrence 
of metastasis associated with the regional lymph 
nodes. Distant failure was metastasis to any site beyond 
the primary tumor and the regional lymph nodes. 
After recurrence or metastasis, patients were given 
salvage therapy as determined by their physicians.
2.3. Statistical analysis
Baseline characteristics were analyzed using t test 
for continuous variables and χ2 test for categorical 
variables. The Kaplan-Meier method was used for 
survival and control analysis [21]. The difference be-
tween the various groups was determined using the 
log-rank test [22]. Cox proportional hazard regres-
sion was used to perform multivariate analysis for 
hazard ratio (HR) assessment. For estimating the ef-
fective size, HR was provided with a 95% confidence 
interval (CI) in addition to a conventional p value. SPSS 
version 12.0 (SPSS Inc., Chicago, IL, USA) was used for 
the analysis of all data. A statistically significant differ-
ence was defined as a p value of less than 0.05.
3. Results
3.1. Patient characteristics
Of the 54 patients evaluated, 11 were stage III and 
43 were stage IV. The patient characteristics and stages 
are presented in Tables 1 and 2. The mean age was 
53.2 years (range, 35–76 years). Most patients were 
men (92.6%, 50/54), and 48 patients (88.9%, 48/54) 
had a history of betel nut chewing.
3.2. Treatment outcome
The median patient follow-up at the commencement 
of the analysis was 25 months (range, 4–104 months). 
Six patients had refused adjuvant treatment. There 
were 48 patients who received RT. The patients who 
received RT had doses ranging from 3960 to 
8100 cGy of radiation (median, 6660 cGy). Forty-one 
of the 48 patients received the full planned dose of 
radiation and seven received an incomplete radiation 
Table 1 — Characteristics of the 54 patients with buccal 
mucosa cancer*
Age
 ≤ 50 yr 24 (44.4)
 > 50 yr 30 (55.6)
Sex
 Male 50 (92.6)
 Female 4 (7.4)
Tumor stage
 T1–2 14 (25.9)
 T3–4 40 (74.1)
Nodal stage
 N0 28 (51.9)
 N1–3 26 (48.1)
Stage
 III 11 (20.4)
 IV 43 (79.6)
Histological differentiation
 Well 4 (7.4)
 Moderate  41 (75.9)
 Poor  7 (13.0)
 Unknown 2 (3.7)
Surgical margin
 < 1 mm 13 (24.1)
 ≥ 1 mm 41 (75.9)
Treatment
 S  6 (11.1)
 S + RT 18 (33.3)
 S + CCRT 30 (55.6)
Smoking
 No 9 (16.7)
 Yes 45 (83.3)
Betel nut chewing
 No 6 (11.1)
 Yes 48 (88.9)
*Data presented as n (%). S = surgery alone; S + RT = surgery + radio-
therapy; S + CCRT = surgery + concurrent chemoradiotherapy.
dose because of treatment-induced complications. 
Fifteen of the 30 patients who received chemotherapy 
completed the full course of chemotherapy and the 
others received less than 4 cycles at a reduced dose. 
When the patients received reduced doses of or a 
limited cycle of chemotherapy, this was due to poor 
compliance because of side effects induced by the 
chemotherapy. Among the six patients without ad-
juvant treatment, two patients, one pT4N2M0 and 
the other pT4N0M0, had locoregional recurrence at 
2 and 7 months and distant metastases at 10 and 11 
Table 2 — Stage distribution of the 54 patients with 
buccal mucosa cancer*
Stage  N0 N1 N2 N3
 T1 – 1 (2) 1 (2) 0 (0)
III (20.4%) T2 – 0 (0) 12 (22) 0 (0)
 T3 9 (17) 1 (2) 4 (7) 0 (0)
IV (79.6%) T4 19 (35) 2 (4) 5 (9) 0 (0)
*Data presented as n (%).
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and disease-specific survivals (Table 4). The pN clas-
sification (pN0 vs. pN1–3) and surgical margin (< 1 
vs. ≥ 1 mm) were the two most significant factors af-
fecting clinical outcome. Straifying pN + into pN1 and 
pN2–3, it was found that pN1 patients had poorer 
3-year locoregional control rates than pN0 patients 
(82% vs. 50%, p = 0.039) but had the same distant 
metastasis-free survival rates as pN0 patients. There 
was no significant difference between pN1 and 
pN2–3 in terms of locoregional control rate (50% vs. 
46%, p = 0.896) and distant metastasis-free survival 
rate (100% vs. 72%, p = 0.268).
4. Discussion
Of the 54 patients, most were men (92.6%, 50/54). 
There were 48 (88.9%) patients who had the habit 
of chewing betel nuts. This epidemiological result 
is similar to other studies carried out in Taiwan. 
Table 3 — The 3-year clinical outcomes according to prognostic factors
Risk factor
 Overall  Disease-specific  Disease-free  Locoregional  Distant 
 survival  p survival  p survival p control rate p metastasis-free p
 (%)  (%)  (%)  (%)  survival (%)
Age
  ≤ 50 yr 61 0.79 61 0.45 62 0.90 74 0.47  86 0.25
  > 50 yr 70  75  56  59   96
Sex
 Male 70 0.07 72 0.28 60 0.18 67 0.40  94 0.22
 Female 25  33  0  0   67
Tumor stage
 T1–2 38* < 0.01 38* < 0.01 39* 0.01 44* 0.008  90 0.80
 T3–4 75  79  66  73   92
Nodal stage
 N(–) 92* < 0.001 96* < 0.001 82* < 0.001 82* 0.001 100* 0.015
 N(+) 33  34  32  46   79
Stage
 III 82 0.3 90 0.16 81 0.23 81 0.43 100 0.27
 IV 59  61  50  57   89
Grade
 1 75 0.9 100 0.38 100 0.19 100 0.25 100 0.58
 2 + 3 64  66  54  61   91
 Surgical margin
 < 1 mm 45* 0.04 49 0.06 42 0.20 48 0.21  84 0.18
 ≥1 mm 73  75  63  70   94
Extracapsular spread
 Positive 25* < 0.01 33 0.08 50 0.32 75 0.98  75 0.18
 Negative 54  54  59  63   91
Perineural invasion
 Positive 67 0.87 67 0.70 56 0.62 67 0.93  89 0.79
 Negative 57  59  57  62   90
Bone invasion
 Positive 63 0.59 84 0.59 50 0.90 50 0.59 100 0.37
 Negative 68  68  62  76   94
Skin invasion
 Positive 74 0.83 80 0.86 82 0.42 100 0.46  82 0.20
 Negative 79  79  70  70  100
*Statistically significant difference (p < 0.05) on univariate analysis.
months. The other four patients were all pT3N0M0 
and had no recurrence or metastases. The 3-year cu-
mulative overall survival, disease-specific survival, 
disease-free survival, locoregional control, and distant 
metastasis-free survival rates for all patients were 
66%, 69%, 58%, 65%, and 92%, respectively.
Univariate analysis for all 54 patients indicated 
that pN classification, surgical margin, and ECS were 
significantly associated with overall survival (Table 3, 
Figs. 1–3). The pN classification also significantly 
affected the locoregional control rate and distant 
metastasis-free survival. For the pN0 and pN + classifi-
cations, the 3-year overall survival, disease-specific 
survival, disease-free survival, locoregional control, 
and distant metastasis-free survival rates were 92%/
33%, 96%/34%, 82%/32%, 82%/46%, and 100%/
79%, respectively (Table 3). On multivariate analysis 
for all patients, pN classification and surgical margin 
significantly affected disease-free survival. The pN clas-
sification also significantly affected overall survival 
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Table 4 — Significant prognostic factors identified by 
multivariate Cox regression analysis
 p
Overall survival
 Nodal stage 0.02
Disease-specific survival
 Nodal stage 0.03
Disease-free survival
 Nodal stage 0.005
 Surgical margin 0.04
Locoregional control rates
 Nodal stage 0.09
Distant metastasis-free survival (–)
Surgical margin < 1 mm
Surgical margin ≥ 1 mm
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Fig. 1 — Kaplan-Meier estimates of overall survival ac-
cording to the cut-off surgical margin.
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Fig. 2 — Kaplan-Meier estimates of overall survival accord-
ing to the pN classification.
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Fig. 3 — Kaplan-Meier estimates of overall survival accord-
ing to the prognostic factor of extracapsular spread (ECS).
The discrepancy in sex reflects the fact that the preva-
lence of betel quid chewing is much higher among 
men than among women in Taiwan [3,4,23].
Buccal cancer is often locally aggressive, with re-
currence rates of 30–80% reported in the literature 
[7–9,24,25]. Locoregional failure is the major cause 
of death for buccal cancers managed with surgery 
and RT. Several studies have demonstrated that the 
status of the surgical margins reported is correlated 
with tumor control [24–26]. Fang et al showed that a 
positive surgical margin and tumor invasion of the 
skin of the cheek were associated with poor prognosis 
[24]. Bernier et al demonstrated that surgical margin 
was an indicator for the adjusted postoperative strat-
egy [17]. In our series, we found that surgical margins 
within 1 mm were correlated with overall survival. 
This factor was also significant in the multivariate 
analysis for disease-free survival. The 3-year overall 
survival for tumors distal to the nearest resection 
margin < 1 mm and ≥ 1 mm were 45%/73% (p = 0.04). 
So, we suggest that surgical margin within 1 mm of a 
buccal cancer should receive stronger postoperative 
treatment.
Several other postoperative prognostic factors 
were evaluated in our study. In addition to surgical 
margin, the pN classification also played an important 
role in our study. We found that pN classification was 
the most important prognostic factor for both survival 
and locoregional control. Compared with other stud-
ies, Diaz et al demonstrated that the 5-year survival 
rate for patients with pN0 and pN + neck were 70% and 
49%, respectively (p = 0.0116) [27]. In addition, Huang 
et al had similar results when pN0 and pN + were com-
pared (78% vs. 41%, p < 0.001) [28]. In this study, the 
significant results for overall survival and locoregional 
control rate among patients with pN0 and pN + disease 
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suggest that intense postoperative adjuvant therapy 
should be given to patients with pN + disease, and 
CCRT with or without targeted therapy in a clinical 
trial setting should be considered.
ECS of involved lymph nodes has been found to 
be a poor prognostic factor. Diaz et al documented 
that cervical metastasis with and without ECS had 
5-year survival rates of 24% and 69%, respectively 
[27]. In our study, the 3-year overall survival for 
ECS(–) and ECS(+) status were 54% and 25%, re-
spectively. However, ECS was significantly associ-
ated with poor survival only in univariate analysis 
but not in multivariate analysis. The reason for this 
may be the limited case numbers or confounding by 
other factors. ECS is often present when multiple 
lymph nodes are involved and its contribution to out-
come may have been masked by the N stage [29].
In the literature, the incidence of systemic dis-
semination in buccal cancer has been found to range 
from 0% to 23% [9,16,24,27,28]. In our study, only 
four (7.4%) patients developed distant metastases, 
with the lungs being the most common site. Loco-
regional failure was the major cause of death and 
remains the main challenge clinically. Thus, how 
local control can be improved is important when fol-
lowing a multimodal treatment strategy.
Since this was a retrospective study, a number of 
factors in terms of patients and tumor characteris-
tics could not be controlled for and may have biased 
the results. However, the presence of lymph node 
involvement, ECS and a surgical margin < 1 mm were 
found to be strong prognostic factors associated 
with tumor control. More aggressive postoperative 
therapy is suggested for patients with buccal mucosa 
carcinoma if these factors exist.
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